ArticleNature communications2026
Boosting pathology foundation models via few-shot prompt-tuning for rare cancer subtyping.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Learnable frozen feature augmentation for few-shot biomarker prediction from pathology whole-slide images.Bioinformatics (Oxford, England) · 2026Article
- Artificial intelligence in multidisciplinary tumor boards enhancing decision making and clinical outcomes in oncology.iScience · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Rare cancers comprise 20-25% of malignancies (over 70% in pediatric oncology) but face major diagnostic challenges due to limited expert availability. While pathology vision-language models show promising zero-shot capabilities for common cancers, their performance on rare cancers remains limited. Existing multi-instance learning (MIL) methods rely solely on visual features, overlooking cross-modal knowledge and compromising interpretability critical for rare cancer diagnosis. To address this, we propose PathPT, a framework that exploits vision-language foundation models through spatially-aware visual aggregation and task-specific prompt tuning. PathPT converts WSI-level supervision into fine-grained tile-level guidance, preserving tumor localization and enabling cross-modal reasoning. Across eight rare and three common cancer datasets-spanning 56 subtypes and 3958 WSIs, PathPT consistently outperforms state-of-the-art methods under data-scarce settings. It achieves substantial gains in both subtyping accuracy and cancerous region grounding ability, providing a scalable, interpretable AI solution to improve rare cancer subtyping with limited access to specialized expertise.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.